Tapemark Acquiring Iontophoretic Technology
Tapemark has agreed to acquire the iontoPatch business from Travanti Pharma Inc., a wholly owned subsidiary of Teikoku Pharma USA Inc. The iontoPatch product line along with iontophoretic technology for use in medical devices and cosmetics will be marketed under the Travanti Medical name.
Tapemark is excited to add the iontoPatch technology to our existing delivery platforms SNAP and SoluStrip both of which support custom manufacturing solutions for a broad range of pharmaceutical, medical device, and consumer products customers around the globe, Andy Rensink, president of Tapemark, stated in a press release.
The iontoPatch product line is currently used in the physical therapy market. Robert Arnold, general manager of the newly formed Travanti Medical, stated in the release: “Combining product design, manufacturing, and regulatory strategy in one entity allows us to more proactively and efficiently address performance enhancements strongly desired by our customers.”
Contract manufacturer Tapemark has several facilities in West St. Paul, MN, serving the medical, pharmaceutical, and consumer products markets. Single-use drug delivery formats include active and passive transdermal patches, topical patches and pads, soluble film, hydrogel, and Tapemark’s patented Snap! packaging.
Tapemark is cGMP-compliant, ISO 9001 and 13485 certified, and FDA registered as a Drug, Device, and Food contract manufacturer. In addition, Tapemark is DEA registered as a Schedule III – V Manufacturer of Controlled Substances. Supporting its expanding global reach, Tapemark is EU-compliant and certified in Japan.